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Abstract 
Background: Use of malaria rapid diagnostic test (mRDT) enhances patient management and reduces costs associ‑
ated with the inappropriate use of antimalarials. Despite its proven clinical effectiveness, mRDT is not readily available 
at licensed chemical shops in Ghana. Therefore, in order to improve the use of mRDT, there is the need to understand 
the willingness to pay for and sell mRDT. This study assessed patients’ willingness to pay and licensed chemical opera‑
tors’ (LCS) willingness to sell mRDTs.
Methods: The study was a cross‑sectional survey conducted in Kintampo North Municipality and Kintampo South 
District of Ghana. Contingent valuation method using the dichotomous approach was applied to explore patient’s 
willingness to pay. In‑depth interviews (IDIs) were used to obtain information from licensed chemical operators’ will‑
ingness to sell.
Results: Majority 161 (97%) of the customers were willing to pay for mRDT while 100% of licensed chemical opera‑
tors were also willing to sell mRDT. The average lowest amount respondents were willing to pay was Ghana cedis 
(GH¢) 1.1 (US$ 0.26) and an average highest amount of GH¢ 2.1 (US$ 0.49). LCS operators were willing to sell the test 
kit at an average lowest price of GH¢1 (US$ 0.23) and average highest price of GH¢2 (US$ 0.47).
Conclusion: Community members were willing to pay for mRDT and LCS operators are willing to sell mRDTs. How‑
ever, the high cost of the mRDT is likely to prevent the widespread use of mRDT. There is a clear need to find system‑
compatible ways to subsidize the use of mRDT via National Health Insurance scheme.
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Background
Malaria kills almost one million people every year and 
affects about half a billion people globally. In 2014 
malaria led to about 214 million cases worldwide and 
about 395,000 deaths in Africa alone [1]. Malaria is one 
of the leading illnesses in Ghana and the main cause of 
mortality and morbidity, accounting for 44% of all out-
patient visits, 37% of all admissions and 11% of deaths 
in the public health facilities [2]. Malaria continues to 
pose economic burden on the health systems although 
the incidence of malaria has decreased. In sub-Saharan 
Africa, an average of US$ 300 million is spent on malaria 
case management each year out of which 23% is spent on 
commodities for diagnosis and treatment [3]. The distri-
bution of antimalarials and use of diagnostic tests at the 
community level by community medicine distributors 
is one of the interventions which has been adopted to 
reduce mortality from malaria [4].
Until recently, the diagnosis and treatment of malaria 
had been presumptive due to lack of diagnostic tools in 
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many health facilities [5, 6]. The practice of presumptive 
malaria diagnosis in Africa has led to over-diagnosis of 
malaria [7–11], over-prescription of antimalarials, and 
undiagnosised or inappropriately treated non-malarial 
febrile illnesses (NMFI) [9, 11]. As a result, the World 
Health Organisation has revised the fever case man-
agement guidelines and now recommends confirmed 
malaria diagnosis before artemisinin-based combination 
therapy (ACT) [12].
In most countries in Africa, large proportions of the 
population utilize the private sector, and in particular 
licensed chemical shops as their first option for treatment 
of fever and malaria [9, 13, 14]. Similar treatment-seeking 
behaviour is seen in Ghana, where an estimated 50% of 
patients, visit drug shops as their first point of care [14–
17] where malaria is diagnosed presumptively.
Malaria rapid diagnostic test (mRDT) has consider-
able potential to improve the diagnosis of malaria [18]. 
Its use in malaria diagnosis is increasing in many coun-
tries as a result of their ease of use with minimal training 
[19]. Using mRDTs for diagnosis at the community level 
will shorten the time between onset of symptoms and 
initiation of appropriate treatment. Use of mRDT will 
help reduce costs by avoiding unnecessary prescription 
of expensive antimalarials and ultimately prevent drug 
resistance among patients, thus reducing other potential 
future costs.
Despite its importance, mRDTs have not yet been 
included in the list of commodities that registered drug 
shops can provide as part of their service under the 
national health insurance scheme in Ghana. Therefore, 
LCS operators will have to sell mRDTs to community 
members for malaria management.
In order to improve the use of mRDTs, there is a need 
to understand issues related to willingness to pay for 
and sell mRDTs. This study assessed the willingness of 
patients to pay for and LCS operators to sell mRDTs.
Methods
Study design
The study was a cross-sectional survey that employed 
both quantitative and qualitative techniques. Data were 
collected between February 2013 and December 2013 
among customers and LCS operators in the Kintampo 
area of Ghana.
Study area
The study was part of a survey which accessed the fea-
sibility of test-based management of malaria by LCS 
operators using mRDT [20]. In the study, participating 
LCS were provided with mRDTs at no cost and sold it 
to the patients at subsidized price. The study was con-
ducted in Kintampo North Municipality and Kintampo 
South District in the middle belt of Ghana. The districts 
covers an area of 7162  km2 with resident population of 
approximately 134,970 [21]. There are two main seasons: 
the rainy season from March to November and dry sea-
son from December to February. The population are sub-
sistence farmers involved in the cultivation of yam and 
maize with increasing activity of petty trading. There are 
two [2] hospitals, 12 health centres/clinics and 26 Com-
munity Health–Based Planning Services (CHPS) com-
pounds. There are three [3] pharmacies and about 68 
LCS in the studied area.
Quantitative data collection methods
The survey was conducted as exit interviews among LCS 
customers seeking treatment for fever or malaria. Partici-
pants were identified as they exited the LCS after seeking 
treatment and their address recorded if they we willing to 
be part of the study. They were later followed–up within 
48  h in their homes for the interviews to be conducted 
to ensure confidentiality and provide a convenient place 
for the interview without any influence from the LCS 
operators. Each LCS operator was visited once by the 
study team and the first 4 clients to the LCS who were 
willing to be part of the study were included in the exit 
interviews.
Contingent valuation method (CVM) was used to 
assess customers willingness to pay using dichotomous 
approach, which is either yes to willingness to pay or the 
opposite [22]. This approach was appropriate for this 
study because at the time of the study, LCS operators 
did not sell mRDTs in the study area. Monetary values 
were determined by asking how much respondents were 
willing-to-pay at a highest and lowest price to have the 
commodity.
The CVM questionnaire was categorized into three 
main groups. Firstly, respondents were asked ques-
tions on their demographics characteristics such as age, 
sex, educational level, marital status and religious back-
ground. Secondly, the questions elicited respondents’ 
willingness to pay for mRDTs that was used to diag-
nose malaria during their visit to the LCS. The highest 
and lowest prices respondents were willing to pay was 
assessed with the assumption that LCS operators would 
sell mRDT. Thirdly, respondents’ socio-economic status 
were assessed using household durable and non-durable 
assets such as ownership of land and farm, motorcycle, 
car, bicycle, radio, household building material for well 
and floor, roofing material, electricity at homes, etc. 
These household assets were used to generate household 
asset scores. Eigen-values were computed using prin-
cipal component analysis, the assets were weighted and 
grouped into various components. The first component 
was used to generate the wealth tertile for participant’s 
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household. This procedure is similar to what was done in 
previous studies [23–25].
Qualitative data collection method
Focus Group Discussions (FGDs) were conducted 
among community members in the community where 
the selected LCSs were located to assess the communi-
ties’ perception of cost of treatment at LCS. An interview 
guide was used to assess reasons for choosing to pay for 
a certain amount and factors influencing their choice. 
Emerging themes relevant to the objectives of the study 
were explored. In-depth interviews (IDIs) were con-
ducted among LCS operators to determine how much 
they are willing to sell mRDT. IDIs were also conducted 
among managers of National Health Insurance Scheme 
(NHIS) to assess potential ways of incorporating mRDTs 
into the scheme.
Sample size
Forty-two out of the 68 LCS in the study area were in 
good standing with the Pharmacy Council (the national 
regulatory body of LCS) and were included in the study. 
A minimum of 4 respondents was interviewed from each 
LCS for logistical reasons. A total of 169 respondents 
were therefore included in the WTP estimation. This 
number provides over 90% power (at α = 0.05) based on 
an assumption of a WTP estimation of about 80% from a 
previously report WTP estimate of 90% [26]. Seven FGDs 
(four with females and three with males), three IDIs 
among LCS operators and six IDIs with NHIS staff were 
conducted.
Data collection, management and analysis
A structured questionnaire was used for data collection. 
Data collection tools were pre-tested prior to its adminis-
tration. All completed data collection tools were received 
in the Kintampo Health Research Centre computer labo-
ratory. Data entry was carried out using Microsoft Excel 
software and transferred to Stata software version 13 
(Stata Corp, Texas, USA). Qualitative data from FGDs 
and IDIs were recorded using digital tapes, transcribed 
and managed with the QRS NVIVO software version 8. 
Categorical demographic data such as educational status, 
sex and socioeconomic were summarised as percentages, 
while continuous variables such as age was summarised 
as means together with their standard deviations.
The outcome measure was defined as respondents’ will-
ingness to pay for mRDT but not dependent on a set cost 
of the mRDT. A secondary outcome measure for univari-
ate and multivariate analysis was defined as respondent’s 
willingness to pay for mRDT at a defined cost of ≤ GHC 
2.00; the price at which LCS sold one mRDT. A logis-
tic regression to explore the factors associated with 
willingness to pay for mRDT was also performed. The 
dependent variable for the regression analysis was WTP 
status which was expressed as yes or no. Variables that 
were found to be associated with WTP in relevant stud-
ies or variables that were significant at p  <  0.25 in the 
univariate analysis were included in the multiple logistic 
model as independent variables (Table 1).
Results
Demographic characteristics
A total of 169 clients attending LCS were recruited to 
participate in the study. Four (2.4%) clients refused par-
ticipation into the study. Seventy-four (44.9%) respond-
ents were males (Table 2). 60.6% of the respondents were 
married. The mean age of the respondents was 30.8 years 
[standard deviation (SD), 15.4 years]. 53.9% of participant 
lived in households which had < 5 children. 42.0% (70) of 
the respondents had not had any formal education. Fifty-
four percent of the respondents had a valid health insur-
ance i.e. were able to access health care with their health 
insurance under the National Health Insurance Scheme.
Willingness‑to‑pay
96.4% (160) of the respondents affirmed their willingness 
to pay for mRDT. Three of the respondents who were not 
willing to pay for mRDT stated that they had valid health 
insurance and therefore, insurance should cover the cost 
of mRDT at LCS just as is being done at health facilities. 
The other two said the cost of mRDT was too high. The 
mean highest and lowest selling price offered by respond-
ents to pay for mRDTs was GH¢ 2.10 (US$ 1.05) (SD 
GH¢ 1.90, range 0.20–15.00) and GH¢ 1.10 (US$0.55) 
(SD GH¢ 0.99, range 0.10–5.00) respectively. Exchange 
rate as at October 2013: US$ 1 is equivalent to GH¢ 2 
[27]. Only 3 (1.9%) respondents were willing to pay above 
GH¢ 7.00 (US$3.5).
Table 1 Definition of variables
Variable Definition
WTP status Dummy variable = 1 for yes, 0 for no
Age Age of respondents in years
16–25 = 1, 26 and above = 2, don’t know = 4
Educational level Level of education of respondent
Non‑formal = 1, formal = 2
NHIS status Insurance status dummy variable
1 = insured, 0 = uninsured
Socio economic status Highest = 1, middle = 2, lowest = 3
Marital status Single, divorced = 1, Married/living 
together = 2
Gender Male = 1, female = 2
Number of children Under 5 = 1, 5–15 = 2, no child = 3
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Factors associated with willingness to pay at the selling 
price of mRDT
Table 3 describes respondents who were willing to pay for 
mRDT at a selling price of ≤ GHC 2 and those who were 
willing to pay above this selling price. 61.6% of respond-
ents who were willing to pay for mRDT at the selling 
price of  ≤  GHC 2 were aged 26 and above (Table  3). 
There was no significant differences in the characteristics 
of respondents who were willing to pay for mRDT at a 
selling price of ≤ GHC 2 compared with that of partici-
pants who were willing to pay > GHC 2.
Factors associated with WTP for mRDT
None of the respondents basic demographic char-
acteristic were found to have an association with 
respondent’s willingness to pay for mRDT. Gender, 
educational level, marital status, number of children, 
insurance status, socio-economic status and age group 
were however included in the multiple logistic regres-
sion (Table  4) since they were found to have an asso-
ciation with the outcome from other studies. Females, 
respondents with higher age group, having a formal 
educational background and married were associated 
with a higher odds of willing to pay compared to males, 
respondents with lower age group, having no educa-
tional background and single when insurance status, 
socio-economic status and the number of children in a 
household are adjusted for. This was however not sta-
tistically significant.
Reasons why respondents were willing to pay for mRDT
Most of the respondents were happy about LCS opera-
tors conducting the mRDT and were willing to pay for it. 
Respondents confirmed that they were previously treated 
presumptively because mRDT were unavailable. They 
appreciate that mRDTs will help improve the quality of 
treatment at LCS.
Table 2 Demographic characteristics of respondents 
(N = 165)
Variable Number of respondents Percentage
Gender
 Male 74 44.9
 Female 91 55.1
Marital status
 Single/divorced 49 29.7
 Married/living together 116 70.3
Age group
 16–25 50 30.3
 26 and above 102 61.8
 Don’t know 13 7.9
Number of children in household
 Under 5 89 53.9
 5–15 41 24.9
 No child 35 21.2
Socio‑economic status
 Highest 55 33.3
 Middle 55 33.3
 Lowest 55 33.3
Form of education
 Non‑formal 70 42.4
 Formal 95 57.6
Religious background
 Christian 90 54.6
 Muslim 68 41.2
 Other 7 4.3
Insurance status
 Insured 89 53.9
 Non‑insured 76 46.1
Table 3 Frequency distribution and analysis of WTP at dif-
ferent price level
Respondent character‑
istics
WTP p value
WTP ≤ GHc2.00
N = 125
n (%)
WTP > 2.00
N = 35
n (%)
Gender
 Male 53 (42.4) 18 (51.4) 0.34
 Female 72 (57.6) 17 (48.6)
Age group
 16–25 38 (30.4) 10 (28.6) 0.98
 26 and above 77 (61.6) 22 (62.9)
 Don’t know 10 (8.0) 3 (8.6)
Level of education
 Non‑formal 52 (41.6) 15 (42.9) 0.89
 Formal 73 (58.4) 20 (57.1)
Marital status
 Single/divorced 37 (29.6) 10 (28.6) 0.91
 Married/living together 88 (70.4) 25 (71.4)
Number of children
 Under 5 70 (56.0) 17 (48.6) 0.69
 5–15 30 (24.0) 9 (25.7)
 No child 25 (20.0) 9 (25.7)
Socio‑economic status
 Highest 42 (33.6) 10 (28.6) 0.83
 Middle 41 (32.8) 13 (37.1)
 Lowest 42 (33.6) 12 (34.3)
Insurance status
 Insured 67 (53.6) 18 (51.4) 0.82
 Non‑insured 58 (46.4) 17 (48.6)
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“It’s good because people think once their head aches 
then they are suffering from malaria which might 
not be true so if the test is been done it will let the 
drug store owner or the one administering the drug 
knows whether the patient is suffering from malaria 
or not and treat the person as such”. [FGD male 
respondent 6, Apesika]
Most respondents agreed to pay for mRDTs for malaria 
management at the LCS because they will save lot of time 
from queuing at health facilities and they also expect 
to get well as early as possible to attend to their farm 
activities.
“It is good because if you are healthy you can do 
anything so I think if we pay for the test and we are 
treated on time, we will get the energy to continue 
with our work. It will also save us time from going to 
health facilities.” [FGD female respondent 3, Amoma]
Reasons why respondents were not willing to pay for mRDT
Respondents who were not willing to pay for mRDT at 
LCS were mainly concerned about poor quality of malaria 
management in LCS if LCS attendants are untrained. 
Respondents who had subscribed to NHIS preferred to 
assess malaria management at NHIS accredited health 
providers to benefit from their subscription. Few of the 
respondents also stated that it will be difficult to pay for 
the test kit because of financial constraint.
“…………………Drug shops are not operated by one 
person and therefore the person who received the 
training will not be the same person to test us with 
the kit” [FGD female respondent 1, Anyima]
“I will rather use my insurance because my insur-
ance has not expired” [FGD male respondent 4, 
Apesika]
“You know for the people living in the smaller com-
munities most of us are farmers and we only get 
money during the harvesting period so I think if 
the test is free it will be good so that we will buy 
the drugs as we used to.” [FGD male respondent 7, 
Gruma]
Willingness to sell
LCS operators were generally happy and willing to sell 
mRDT to their customers because it will help them sell 
the right medication to their customers. They suggested a 
lowest selling price of GH¢ 0.50 and highest price of GH¢ 
2.00.
“the lowest cost should be GH¢ 0.50 and the highest 
price that the RDT must be sold is GH¢ 1.00. This 
will help the patients to afford the cost in addition to 
the drugs.” [IDI LCS operator 1]
However, there were some challenges that were iden-
tified that may affect mRDT sales at the LCS. They per-
ceived irregular supply and stock outs of mRDT to be a 
major barrier to effective management of malaria. This 
potential barrier may also make customers lose confi-
dence in LCS operators.
“The difficulty in restocking is the problem of dis-
tance and the frequency of supply. Assuming I am 
supplied one box of malaria drugs today and it get 
finish today I still have to wait for the next supply 
period to be able to restock and that is the challenge. 
We don’t actually get supply daily and frequently 
because some suppliers come even after one month 
of supply so we always have to wait between these 
periods”. [IDI LCS operator 3]
LCS operators were concerned about the affordability 
of mRDTs by their customers who are mainly rural and 
of low socioeconomic level. They indicated the cost of 
Table 4 Multiple Logistic regression showing the relation-
ship between respondent’s willingness to pay and their 
demographic characteristics
S. E Standard error, CI confidence interval
Odds ratio S. E p value 95% CI
Gender
 Male 1
 Female 5.20 6.15 0.16 0.51–52.85
Age
 Below 26 years 1
 26 years and above 2.68 3.54 0.46 0.20–35.74
Educational level
 No formal education 1
 Formal education 2.01 2.67 0.60 0.15–27.39
NHIS status
 No 1
 Yes 0.17 0.21 0.15 0.14–1.92
Socio‑economic status
 Lowest 1
 Middle 0.94 1.42 0.96 0.49–18.19
 Highest 0.16 0.22 0.18 0.11–2.36
Marital status
 Single 1
 Married 3.47 4.81 0.37 0.23–52.35
Number of children
 None 1
 1–5 children 0.34 0.74 0.62 0.01–24.15
 6 children and above 0.18 0.44 0.49 0.01–23.17
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malaria management will be higher if the cost of mRDTs 
is added to the already high cost of ACTs.
“I suggest that we sell the test kit at one Ghana cedi 
so that people can get enough to buy the accompany-
ing drugs after the test”. [IDI LCS operator 2].
mRDT under NHIS
The NHIS staff found it important to register mRDT 
under the NHIS as one of the services that LCS can pro-
vide since LCS are the first point of contact for health 
care in the community. However, they perceive some 
challenges when LCS operators are allowed to sell mRDT. 
NHIA deals with government institutions and private 
registered companies but in general, some of the LCS are 
not registered or are not in good standing with the Phar-
macy Council of Ghana.
“the LCS operators should be registered with the 
Pharmacy Council and then they can be accredited 
under the NHIS so that incase of any legalities and 
malfeasants, they can be taken to court” (NHIS staff 
respondent 1)
Another challenge that respondents spoke about was 
that NHIS is migrating from paper based to an electronic 
system of operations including claims and reimburse-
ment. The NHIS staff perceive the system to be com-
plex for the education level of LCS operators and also 
resource intensive as outlined below.
“……..those who will be permitted to sell the mRDT 
under NHIS should be LCS operators who are prop-
erly trained and is capable of handling the biometric 
issues”. [NHIS staff respondent 2].
NHIS intends assign each subscriber to specific NHIS 
accredited health service providers. NHIS subscribers 
have a choice in selecting a service provider. Therefore, it is 
unlikely that NHIS subscriber will choose LCS as their pre-
ferred choice for health care over other higher level health 
facilities. The NHIS staff perceive the preference of larger 
hospitals to be a challenge for LCS if they are to be accred-
ited by NHIS as service providers for malaria management. 
The
“under the capitation it will be very difficult for people 
to choose drug shops as their primary provider because 
if you seek care from them and they are not able to help 
where will you go?” [NHIS staff respondent 1]
Discussion
This study assessed community members’ willingness to 
pay for malaria rapid diagnostic test (mRDT). The major-
ity of respondents (97%) were willing to pay for mRDTs at 
the LCS but at a price lower than its actual selling price 
(< GH¢ 2). To ensure test based malaria management at 
the community level, the price of mRDT should therefore 
be less than the cost price of mRDTs [GH¢ 7.3 (U$ 3.7)] 
at the time of the study. This finding is consistent with a 
related study carried out in Uganda where a majority of 
respondents were unwilling to pay a price higher than 
the subsidized price of US$ 2.49 [28]. This observation 
is however different from a similar study conducted in 
Nigeria [26], where the authors found respondents will-
ing to pay higher price than the selling price. The differ-
ence may be because Nigeria’s per capita income ($ 2966) 
is higher than that of Ghana ($ 1846). The lower price 
placed on mRDT by the respondents was mainly due 
to their inability to afford mRDT and ACT at the same 
time. Another factor was that malaria test is done at no 
cost in health facilities as part of the benefit of the NHIS 
and therefore, mRDT should also be free at LCS. These 
factors were different from findings of Rennie et al. [29] 
where a low price was offered for mRDT because malaria 
was not perceived a serious disease compared to other 
illness such as syphilis and HIV. If community members 
are encouraged to access mRDT at affordable prices in 
the drug shops, it will help reduce over utilization of anti-
malarials and also lead to appropriate treatment of other 
febrile illnesses. Hansen et  al. concluded in their study 
that the subsidized price of mRDT should be lower than 
the subsidized price of ACT to ensure a large percentage 
of community members to patronize mRDT at LCS [28].
To enable majority of community members patronize 
mRDT at LCS, the government and other donor agencies 
should subsidize the mRDT as it has been done for other 
interventions like insecticide treated nets, childhood 
immunizations. Recently ACTs were subsidized by spe-
cial programmes such as Affordable Medicines Facility 
for Malaria (AMFm) to enhance accessibility and afford-
ability of ACTs at the community level. This program 
has led to a sustained reduction of the cost of ACTs in 
Ghana and other African countries [30–32]. These pro-
grammes were resistant to escalating cost of ACTs that 
arise of exchange rates. A similar program for mRDTs 
will enhance the quality of malaria management at the 
community.
The respondents in our study recognized the benefits 
malaria diagnosis with mRDT at the LCS and found the 
approach acceptable. Their perception of a benefit was 
expressed mainly in terms of economic gains such as 
time saving for their economic activities. This observa-
tion was similar to other studies [26, 28]. This perceived 
benefit is an important observation to use as a communi-
cation message on the importance of mRDT.
In determining factors associated with WTP using the 
logistic regression, respondent’s household with larger 
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number of children were associated with a lower odds of 
willing to pay which can be interpreted as a lesser willing-
ness to pay for mRDT as the number of household chil-
dren increases. This is contrary to the expectation that 
the more children one has, the more willing one will be to 
pay for mRDT. Though not statistically significant, demo-
graphic variables such as females, increasing age, bet-
ter education and being married had a higher odds with 
respondents’ willingness to pay for mRDT. This finding 
is similar to that found in other studies in Uganda, and 
Tanzania [28, 29]. In these studies, demographic charac-
teristics such as educated respondents were more likely 
to pay for mRDT than uneducated respondents. Health 
promotion interventions should therefore target demo-
graphic groups who are less likely to pay for mRDT to 
ensure appropriate management of mRDTs.
All LCS operators were willing to sell mRDT and use 
it as part of their malaria management. It is likely they 
are motivated both by the potential improvement in 
the quality of malaria diagnosis when using mRDT as 
well as by having a (higher) profit through markups on 
the mRDT. There is therefore the need to maintain or 
enhance their motivation to use mRDTs by (i) ensuring 
an adequate mRDT supply chain to the LCS and (ii) sup-
porting a selling price that at least does not leave the LCS 
operators worse off.
NHIS staff found it acceptable to integrate the mRDT 
as part of malaria management at LCS, but pointed out 
challenges in terms of health insurance data management 
at the LCS and the new NHIS reimbursement model. 
NHIS service providers are required to provide data 
using a data management tool that requires internet and 
computers. This challenge could be overcome through 
novel approaches such use of different technology, e.g. 
mHealth using smart phones. Studies have shown that 
basic electronic information systems have been used by 
community health officers and community members to 
report health indices [33–36]. It is likely that LCS can be 
trained to provide the required electronic data to NHIS. 
The other potential challenge is the proposed reimburse-
ment system for NHIS in Ghana that provides an advance 
payment accredited health service providers for each 
individual assigned to them over a fixed period of time 
(capitation payment mechanism). Under this mecha-
nism, it is likely that NHIS subscribers will not choose 
the LCS as their primary service provider since the ser-
vices of LCS is limited in scope. However, since malaria 
is the leading cause of morbidity in Ghana and LCS are 
the first point of call for febrile illnesses, a pragmatic 
approach such as exemption of LCS from the capitation 
mechanism should be carefully tested in order to meet 
the needs of community members. Conversely, a special 
package of capitation payment can be piloted in LCS to 
meet the needs of community members. In addition to 
such a package, there is the need for a strong referral sys-
tem to ensure LCS refer patients to higher facilities after 
they have been treated with ACTs and symptoms still 
persist. The referral system should be audited by health 
authorities to avoid the risk of misdiagnosis at the LCS.
Study limitations
This study has some limitation as it was nested into a 
study which provided the LCS with mRDT at subsided 
price and sold it to customers at very low price. This limi-
tation may have influenced the customers’ perception of 
the “highest and lowest price that they are willing to pay”. 
The study sample size was small and therefore may not 
be representative of the entire population of those who 
seek care from LCS. The study results may be potentially 
biased and reflective of a largely homogeneous popula-
tion in a rural area. However, the study setting is typical 
of other rural areas in Ghana were availability of mRDT 
at LCS is required most. Another potential source of bias 
may arise from participants over estimation of their will-
ingness to pay as a result of their intense need or antici-
pation for quality malaria care. Currently, the use of 
mRDT by LCS is a policy in Ghana and it will therefore 
be important to repeat this study in a real-life setting.
Conclusion
Community members were willing to pay for mRDT and 
LCS are willing to sell mRDTs. However, a high cost of 
the mRDT is likely to be a deterrent to community mem-
bers who are willing to patronize mRDT. The authors 
suggest to review options for subsidizing the price of 
mRDT at LCS.
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